UB
Ulisse Biomed S.p.A.
UBM.MI · MIL
0.81 € +0.00% (+0.00 €)
Market Cap 19.6M €
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
50 /100
Fair P/S 48.16x
P/B 0.64x
P/E N/A
Growth
100 /100
Growing Rev. growth 132.61%
Book val. growth 107.26%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 51.14%
Net margin 358.75%
FCF margin 378.38%
Quality
0 /100
Poor ROIC 4.74%
ROA 4.65%
Asset turnover 0.01x
Debt
73 /100
Low Debt/Equity 0.00x
Current ratio 2.63x
Net debt/EBITDA 1.32x
Stability
26 /100
Unstable Beta 0.80x
Rev. volatility 2,218.56%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about UBM.MI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Nicola Basile
Employees
8
Headquarters
Udine